Newbury Pharma signs license, supply deal with existing partner to launch guanfacine in Sweden

Reuters2026/08/17 13:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Newbury signed a license and supply deal with an existing partner to register, supply, and launch guanfacine tablets in Sweden.
Product targets ADHD in children and adolescents; prolonged-release tablets in 1 mg to 4 mg strengths.
Regulatory filing expected soon; launch planned following approval.
Relevant Swedish market estimated at EUR 17 million annually, based on DLMI Nordic Pharma Insights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Newbury Pharmaceuticals AB published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Newbury Pharma signs license, supply deal with existing partner to launch guanfacine in Sweden

You may also like

Crypto prices